长非编码RNA调控骨肉瘤耐药机制的研究进展

doi:10.3760/cma.j.cn371439-20221005-00010

国际肿瘤学杂志 ›› 2023, Vol. 50 ›› Issue (1): 51-54.doi: 10.3760/cma.j.cn371439-20221005-00010

长非编码RNA调控骨肉瘤耐药机制的研究进展

马小平, 常君丽, 孙星媛, 杨燕萍()

上海中医药大学附属龙华医院脊柱病研究所教育部筋骨理论与治法重点实验室，上海 200032

收稿日期:2022-10-05 修回日期:2022-11-06 出版日期:2023-01-08 发布日期:2023-03-16
通讯作者: 杨燕萍 E-mail:yanpingyang@shutcm.edu.cn
基金资助:
国家重点研发计划(2018YFC1704300);国家重点研发计划(2020YFE0201600);国家自然科学基金(81973877);国家自然科学基金(82174408)

Study progression on mechanism of long non-coding RNAs regulating drug resistance in osteosarcoma

Ma Xiaoping, Chang Junli, Sun Xingyuan, Yang Yanping()

Spine Disease Research Institute， Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine；Key Laboratory of Theory and Therapy of Muscles and Bones， Ministry of Education， Shanghai 200032， China

Received:2022-10-05 Revised:2022-11-06 Online:2023-01-08 Published:2023-03-16
Contact: Yang Yanping E-mail:yanpingyang@shutcm.edu.cn
Supported by:
National Key Research and Development Program of China(2018YFC1704300);National Key Research and Development Program of China(2020YFE0201600);National Natural Science Foundation of China(81973877);National Natural Science Foundation of China(82174408)

摘要/Abstract

摘要：

骨肉瘤是最常见的原发性实体骨恶性肿瘤，化疗药物的耐药是导致骨肉瘤复发和转移的重要因素。长非编码RNA可通过调节上皮间质转化、细胞自噬、凋亡、药物外排、细胞周期等途径影响骨肉瘤耐药，提示长非编码RNA可能成为治疗骨肉瘤耐药的新靶点。

关键词: RNA，长链非编码, 骨肉瘤, 抗药性，肿瘤

Abstract:

Osteosarcoma is the most common primary solid bone malignancy. The main factor leading to recurrence and metastasis of osteosarcoma is resistance to chemotherapy drugs. Long non-coding RNAs can affect drug resistance in osteosarcoma by regulating epithelial-mesenchymal transition， cell autophagy， apoptosis， drug efflux， and cell cycle， suggesting that long non-coding RNAs may become new targets for drug resistance in osteosarcoma treatment.

Key words: RNA， long non-coding, Osteosarcoma, Drug resistance， neoplasms

马小平, 常君丽, 孙星媛, 杨燕萍. 长非编码RNA调控骨肉瘤耐药机制的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 51-54.

Ma Xiaoping, Chang Junli, Sun Xingyuan, Yang Yanping. Study progression on mechanism of long non-coding RNAs regulating drug resistance in osteosarcoma[J]. Journal of International Oncology, 2023, 50(1): 51-54.

参考文献 31

[1]	Wu W, Jing D, Meng Z, et al. FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity[J]. Theranostics, 2020, 10(6): 2859-2871. DOI: 10.7150/thno.41279. doi: 10.7150/thno.41279 pmid: 32194840
[2]	Davis LE, Janeway KA, Weiss AR, et al. Clinical trial enrollment of adolescents and young adults with sarcoma[J]. Cancer, 2017, 123(18): 3434-3440. DOI: 10.1002/cncr.30757. doi: 10.1002/cncr.30757 pmid: 28493547
[3]	Li Z, Li X, Xu D, et al. An update on the roles of circular RNAs in osteosarcoma[J]. Cell Prolif, 2021, 54(1): e12936. DOI: 10.1111/cpr.12936. doi: 10.1111/cpr.12936
[4]	Sasaki R, Osaki M, Okada F. MicroRNA-based diagnosis and treatment of metastatic human osteosarcoma[J]. Cancers (Basel). 2019, 11(4): 553. DOI: 10.3390/cancers11040553. doi: 10.3390/cancers11040553
[5]	Gill J, Gorlick R. Advancing therapy for osteosarcoma[J]. Nat Rev Clin Oncol, 2021, 18(10): 609-624. DOI: 10.1038/s41571-021-00519-8. doi: 10.1038/s41571-021-00519-8 pmid: 34131316
[6]	张俊鹏, 于燕燕, 李宝生. lncRNA、circRNA调控食管鳞状细胞癌放化疗敏感性的作用机制[J]. 国际肿瘤学杂志, 2022, 49(3): 185-189. DOI: 10.3760/cma.j.cn371439-20220104-00032. doi: 10.3760/cma.j.cn371439-20220104-00032
[7]	Qian X, Zhao J, Yeung PY, et al. Revealing lncRNA structures and interactions by sequencing-based approaches[J]. Trends Biochem Sci, 2019, 44(1): 33-52. DOI: 10.1016/j.tibs.2018.09.012. doi: S0968-0004(18)30197-X pmid: 30459069
[8]	Wang JY, Yang Y, Ma Y, et al. Potential regulatory role of lncRNA-miRNA-mRNA axis in osteosarcoma[J]. Biomed Pharmacother, 2020, 121: 109627. DOI: 10.1016/j.biopha.2019.109627. doi: 10.1016/j.biopha.2019.109627
[9]	Liu SJ, Dang HX, Lim DA, et al. Long noncoding RNAs in cancer metastasis[J]. Nat Rev Cancer, 2021, 21(7): 446-460. DOI: 10.1038/s41568-021-00353-1. doi: 10.1038/s41568-021-00353-1 pmid: 33953369
[10]	Noronha C, Ribeiro AS, Taipa R, et al. Cadherin expression and EMT: a focus on gliomas[J]. Biomedicines, 2021, 9(10): 1328. DOI: 10.3390/biomedicines9101328. doi: 10.3390/biomedicines9101328
[11]	Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis[J]. Trends Cell Biol, 2019, 29(3): 212-226. DOI: 10.1016/j.tcb.2018.12.001. doi: S0962-8924(18)30201-0 pmid: 30594349
[12]	Li R, Ruan Q, Zheng J, et al. LINC01116 promotes doxorubicin resistance in osteosarcoma by epigenetically silencing miR-424-5p and inducing epithelial-mesenchymal transition[J]. Front Pharmacol, 2021, 12: 632206. DOI: 10.3389/fphar.2021.632206. doi: 10.3389/fphar.2021.632206
[13]	Kun-Peng Z, Chun-Lin Z, Xiao-Long M, et al. Fibronectin-1 modulated by the long noncoding RNA OIP5-AS1/miR-200b-3p axis contributes to doxorubicin resistance of osteosarcoma cells[J]. J Cell Physiol, 2019, 234(5): 6927-6939. DOI: 10.1002/jcp.27435. doi: 10.1002/jcp.27435 pmid: 30204936
[14]	Usman RM, Razzaq F, Akbar A, et al. Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance[J]. Asia Pac J Clin Oncol, 2021, 17(3): 193-208. DOI: 10.1111/ajco.13449. doi: 10.1111/ajco.13449
[15]	Wang K, Du B, Xu B, et al. JMJD6-STAT3^Y705ph axis promotes autophagy in osteosarcoma cancer cells by regulating ATG[J]. Biofactors, 2020, 46(5): 839-848. DOI: 10.1002/biof.1614. doi: 10.1002/biof.1614
[16]	Zhu K, Yuan Y, Wen J, et al. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22[J]. Aging (Albany NY), 2020, 12(8): 6644-6666. DOI: 10.18632/aging.103004. doi: 10.18632/aging.103004
[17]	Zhang J, Rao D, Ma H, et al. LncRNA SNHG15 contributes to doxorubicin resistance of osteosarcoma cells through targeting the miR-381-3p/GFRA1 axis[J]. Open Life Sci, 2020, 15(1): 871-883. DOI: 10.1515/biol-2020-0086. doi: 10.1515/biol-2020-0086 pmid: 33817274
[18]	D'Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy[J]. Cell Biol Int, 2019, 43(6): 582-592. DOI: 10.1002/cbin.11137. doi: 10.1002/cbin.11137 pmid: 30958602
[19]	Zhou B, Li L, Li Y, et al. Long noncoding RNA SNHG12 mediates doxorubicin resistance of osteosarcoma via miR-320a/MCL1 axis[J]. Biomed Pharmacother, 2018, 106: 850-857. DOI: 10.1016/j.biopha.2018.07.003. doi: S0753-3322(18)32968-8 pmid: 30119255
[20]	Liu L, Wang S. Long non-coding RNA OIP5-AS1 knockdown enhances CDDP sensitivity in osteosarcoma via miR-377-3p/FosL2 axis[J]. Onco Targets Ther, 2020, 13: 3853-3866. DOI: 10.2147/OTT.S232918. doi: 10.2147/OTT.S232918
[21]	Hu Y, Yang Q, Wang L, et al. Knockdown of the oncogene lncRNA NEAT1 restores the availability of miR-34c and improves the sensitivity to cisplatin in osteosarcoma[J]. Biosci Rep, 2018, 38(3): BSR20180375. DOI: 10.1042/BSR20180375. doi: 10.1042/BSR20180375
[22]	Haider T, Pandey V, Banjare N, et al. Drug resistance in cancer: mechanisms and tackling strategies[J]. Pharmacol Rep, 2020, 72(5): 1125-1151. DOI: 10.1007/s43440-020-00138-7. doi: 10.1007/s43440-020-00138-7
[23]	Wang JQ, Yang Y, Cai CY, et al. Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance[J]. Drug Resist Updat, 2021, 54: 100743. DOI: 10.1016/j.drup.2021.100743. doi: 10.1016/j.drup.2021.100743
[24]	Han Z, Shi L. Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis[J]. Biochem Biophys Res Commun, 2018, 495(1): 947-953. DOI: 10.1016/j.bbrc.2017.11.121. doi: 10.1016/j.bbrc.2017.11.121
[25]	Tang R, Zhang Z, Han W. CircLRRK1 targets miR-223-3p to inhibit the proliferation, migration and invasion of trophoblast cells by regulating the PI3K/Akt signaling pathway[J]. Placenta, 2021, 104: 110-118. DOI: 10.1016/j.placenta.2020.12.003. doi: 10.1016/j.placenta.2020.12.003 pmid: 33310596
[26]	Wang B, Cao C, Liu X, et al. BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/Akt/mTOR signalling pathway[J]. Cell Oncol, 2020, 43(2): 223-235. DOI: 10.1007/s13402-019-00482-8. doi: 10.1007/s13402-019-00482-8
[27]	Zhou B, Xiang J, Zhan C, et al. STK33 promotes the growth and progression of human pancreatic neuroendocrine tumour via activation of the PI3K/Akt/mTOR pathway[J]. Neuroendocrinology, 2020, 110(3-4): 307-320. DOI: 10.1159/000501829. doi: 10.1159/000501829 pmid: 31261148
[28]	Song L, Zhou Z, Gan Y, et al. Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/Akt/mTOR signaling pathway by sponging the miR-340-5p[J]. J Cell Biochem, 2019, 120(6): 9656-9666. DOI: 10.1002/jcb.28244. doi: 10.1002/jcb.28244 pmid: 30548308
[29]	Sun ZY, Jian YK, Zhu HY, et al. lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/Akt pathway[J]. Pathol Res Pract, 2019, 215(3): 555-563. DOI: 10.1016/j.prp.2018.12.013. doi: 10.1016/j.prp.2018.12.013
[30]	Zhang L, Zhao G, Ji S, et al. Downregulated long non-coding RNA MSC-AS1 inhibits osteosarcoma progression and increases sensitivity to cisplatin by binding to microRNA-142[J]. Med Sci Monit, 2020, 26: e921594. DOI: 10.12659/MSM.921594. doi: 10.12659/MSM.921594
[31]	Wang F, Kong L, Pu Y, et al. Long noncoding RNA DICER1-AS1 functions in methylation regulation on the multi-drugresistance of osteosarcoma cells via miR-34a-5p and GADD45A[J]. Front Oncol, 2021, 11: 685881. DOI: 10.3389/fonc.2021.685881. doi: 10.3389/fonc.2021.685881

长非编码RNA调控骨肉瘤耐药机制的研究进展

Study progression on mechanism of long non-coding RNAs regulating drug resistance in osteosarcoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 31

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[2]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[3]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛. 铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[4]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[5]	柳洋, 蒋路路, 管凯文, 周岳阳, 康小红. linc01410在恶性肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2023, 50(9): 540-543.
[6]	安荣, 刘美华, 王佩晨, 王晓慧. Nrf2在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(8): 493-497.
[7]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳. 沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[8]	拜莹, 李琦, 李亚芹, 赵卫红. E2F1与lncRNA在恶性肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2023, 50(3): 164-168.
[9]	刘小洁, 黄俊星. NADPH氧化酶2在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(10): 618-621.
[10]	闫学敏, 武霄勇, 张佳谊, 文锦旭, 王跃欣. SPRY4-IT1与乳腺癌[J]. 国际肿瘤学杂志, 2023, 50(10): 627-630.
[11]	王熙, 吴川清. 结直肠癌多药耐药逆转的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 42-46.
[12]	周仁邦, 张仲传, 许志远, 朱勋兵. miR-219a-5p通过负调控HMGA2抑制骨肉瘤U2OS细胞增殖、侵袭和迁移[J]. 国际肿瘤学杂志, 2022, 49(4): 193-198.
[13]	洪安澜, 曹蒙, 王焱, 方方. 长非编码RNA作为竞争性内源RNA在黑色素瘤中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(1): 61-64.
[14]	张静, 黄守国, 夏鹰. CeRNA网络介导恶性肿瘤表型调控的机制研究[J]. 国际肿瘤学杂志, 2021, 48(9): 544-548.
[15]	陈佩瑶, 贾军梅. 缺氧影响免疫治疗耐药的机制与应用[J]. 国际肿瘤学杂志, 2021, 48(8): 489-493.